[Case report of kidney cancer from JOUM 2010].
Fiche publication
Date publication
mars 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LANG Hervé
Tous les auteurs :
Neuzillet Y, Guy L, Long JA, Zini L, Chevreau C, Duclos B, Escudier B, Gimel P, Joly F, Lang H, Mejean A, Oudard S, Roumeguere T
Lien Pubmed
Résumé
Three clinical cases have shown the superiority of sunitinib in first line therapy intermediate risk metastatic clear cell renal carcinoma and a best safety of bevacizumab plus interferon, the current lack of high level of evidence arguments for the neo-adjuvant treatment of kidney cancer, the importance to prevent mucositis during a mTOR inhibitors treatment and the diagnostic pitfalls of its pulmonary complications.
Référence
Prog Urol. 2011 Mar;21 Suppl 2:S27-33.